122 related articles for article (PubMed ID: 29894293)
21. Long non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in colorectal cancer progression.
Li Y; Zeng C; Hu J; Pan Y; Shan Y; Liu B; Jia L
J Hematol Oncol; 2018 Jul; 11(1):89. PubMed ID: 29970122
[TBL] [Abstract][Full Text] [Related]
22. Immature O-glycans recognized by the macrophage glycoreceptor CLEC10A (MGL) are induced by 4-hydroxy-tamoxifen, oxidative stress and DNA-damage in breast cancer cells.
Kurze AK; Buhs S; Eggert D; Oliveira-Ferrer L; Müller V; Niendorf A; Wagener C; Nollau P
Cell Commun Signal; 2019 Aug; 17(1):107. PubMed ID: 31455323
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers.
Sun X; Ju T; Cummings RD
BMC Cancer; 2018 Aug; 18(1):827. PubMed ID: 30115016
[TBL] [Abstract][Full Text] [Related]
24. Glycosylation-dependent interactions of C-type lectin DC-SIGN with colorectal tumor-associated Lewis glycans impair the function and differentiation of monocyte-derived dendritic cells.
Nonaka M; Ma BY; Murai R; Nakamura N; Baba M; Kawasaki N; Hodohara K; Asano S; Kawasaki T
J Immunol; 2008 Mar; 180(5):3347-56. PubMed ID: 18292560
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer.
Cheng HH; Lin JK; Chen WS; Jiang JK; Yang SH; Chang SC
Int J Colorectal Dis; 2018 Sep; 33(9):1173-1181. PubMed ID: 29869121
[TBL] [Abstract][Full Text] [Related]
26. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
27. Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation.
Chugh S; Meza J; Sheinin YM; Ponnusamy MP; Batra SK
Br J Cancer; 2016 Jun; 114(12):1376-86. PubMed ID: 27187683
[TBL] [Abstract][Full Text] [Related]
28. Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma.
Condelli V; Maddalena F; Sisinni L; Lettini G; Matassa DS; Piscazzi A; Palladino G; Amoroso MR; Esposito F; Landriscina M
Oncotarget; 2015 Sep; 6(26):22298-309. PubMed ID: 26084290
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
[TBL] [Abstract][Full Text] [Related]
30. LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway.
Liu B; Pan S; Xiao Y; Liu Q; Xu J; Jia L
J Exp Clin Cancer Res; 2018 Dec; 37(1):316. PubMed ID: 30547804
[TBL] [Abstract][Full Text] [Related]
31. Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation.
Napoletano C; Zizzari IG; Rughetti A; Rahimi H; Irimura T; Clausen H; Wandall HH; Belleudi F; Bellati F; Pierelli L; Frati L; Nuti M
Eur J Immunol; 2012 Apr; 42(4):936-45. PubMed ID: 22531918
[TBL] [Abstract][Full Text] [Related]
32. MGL Receptor and Immunity: When the Ligand Can Make the Difference.
Zizzari IG; Napoletano C; Battisti F; Rahimi H; Caponnetto S; Pierelli L; Nuti M; Rughetti A
J Immunol Res; 2015; 2015():450695. PubMed ID: 26839900
[TBL] [Abstract][Full Text] [Related]
33. Aberrant Cosmc genes result in Tn antigen expression in human colorectal carcinoma cell line HT-29.
Yu X; Du Z; Sun X; Shi C; Zhang H; Hu T
Int J Clin Exp Pathol; 2015; 8(3):2590-602. PubMed ID: 26045765
[TBL] [Abstract][Full Text] [Related]
34. GALNT2 promotes invasiveness of colorectal cancer cells partly through AXL.
Liao YY; Chuang YT; Lin HY; Lin NY; Hsu TW; Hsieh SC; Chen ST; Hung JS; Yang HJ; Liang JT; Huang MC; Huang J
Mol Oncol; 2023 Jan; 17(1):119-133. PubMed ID: 36409270
[TBL] [Abstract][Full Text] [Related]
35. The C-type lectin macrophage galactose-type lectin impedes migration of immature APCs.
van Vliet SJ; Paessens LC; Broks-van den Berg VC; Geijtenbeek TB; van Kooyk Y
J Immunol; 2008 Sep; 181(5):3148-55. PubMed ID: 18713985
[TBL] [Abstract][Full Text] [Related]
36. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
[TBL] [Abstract][Full Text] [Related]
37. C1GalT1 expression reciprocally controls tumour cell-cell and tumour-macrophage interactions mediated by galectin-3 and MGL with double impact on cancer development and progression.
Wan Y; Adair K; Herrmann A; Shan X; Xia L; Duckworth CA; Yu LG
Cell Death Dis; 2023 Aug; 14(8):547. PubMed ID: 37612278
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and prognostic relevance of BrafV600E mutation in colorectal carcinomas from Kashmir (North India) valley.
Eachkoti R; Farooq S; Syeed SI; Wani HA; Majid S; Pampori MR
Mutagenesis; 2018 Sep; 33(3):225-230. PubMed ID: 29800258
[TBL] [Abstract][Full Text] [Related]
39. Clinically significant missense variants in human GALNT3, GALNT8, GALNT12, and GALNT13 genes: intriguing in silico findings.
Hussain MRM; Nasir J; Al-Aama JY
J Cell Biochem; 2014 Feb; 115(2):313-27. PubMed ID: 24038392
[TBL] [Abstract][Full Text] [Related]
40. Tumor-associated Neu5Ac-Tn and Neu5Gc-Tn antigens bind to C-type lectin CLEC10A (CD301, MGL).
Mortezai N; Behnken HN; Kurze AK; Ludewig P; Buck F; Meyer B; Wagener C
Glycobiology; 2013 Jul; 23(7):844-52. PubMed ID: 23507963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
